(Q54043285)

24 May 2018

review article

1 reference

title

[Antibiotic therapy in cystic fibrosis. II Antibiotic strategy] (English)

1 reference

24 May 2018

main subject

cystic fibrosis

0 references

author

Isabelle Sermet-Gaudelus

1

object named as

Sermet-Gaudelus I

1 reference

24 May 2018

Gérard Lenoir

6

object named as

Lenoir G

1 reference

24 May 2018

author name string

Ferroni A

2

1 reference

24 May 2018

Gaillard JL

3

1 reference

24 May 2018

Silly C

4

1 reference

24 May 2018

Chretiennot C

5

1 reference

24 May 2018

Berche P

7

1 reference

24 May 2018

publication date

1 June 2000

1 reference

24 May 2018

published in

Archives de Pediatrie

1 reference

24 May 2018

volume

7

1 reference

24 May 2018

page(s)

645-656

1 reference

24 May 2018

issue

6

1 reference

24 May 2018

Management of pulmonary disease in patients with cystic fibrosis

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Microbiology of sputum from patients at cystic fibrosis centers in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

The innate immune system in cystic fibrosis lung disease

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

The genesis of cystic fibrosis lung disease

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Pseudomonas cepacia: a new pathogen in patients with cystic fibrosis referred to a large centre in the United Kingdom

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Correlation between activity of beta-lactam agents in vitro and bacteriological outcome in acute pulmonary exacerbations of cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Interaction of aminoglycosides and cephalosporins against Pseudomonas aeruginosa. Correlation between interaction index and killing curve.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Randomized trial of ceftazidime versus placebo in the management of acute respiratory exacerbations in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Are antipseudomonal antibiotics really beneficial in acute respiratory exacerbations of cystic fibrosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Antimicrobial treatment of pulmonary colonization and infection by pseudomonas aeruginosa in cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Is anti-Pseudomonas therapy warranted in acute respiratory exacerbations in children with cystic fibrosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Haemophilus infection in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Antibiotic choice for Pseudomonas pulmonary infections in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Comparison of antibacterial activities of meropenem and six other antimicrobials against Pseudomonas aeruginosa isolates from North American studies and clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Comparative study of the antibacterial activity of amikacin and tobramycin during Pseudomonas pulmonary infection in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Ceftazidime, gentamicin, and rifampicin, in combination, kill biofilms of mucoid Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Long-term azithromycin may improve lung function in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Suppression of virulence factors of Pseudomonas aeruginosa by erythromycin

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Inhibitory effect of antimicrobial agents on alginate production in Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Erythromycin inhibits respiratory glycoconjugate secretion from human airways in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Azithromycin, the multidrug-resistant protein, and cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Anti-inflammatory effects of macrolide antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Effect of clarithromycin on lymphocytes in chronic respiratory Pseudomonas aeruginosa infection

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Tolerance, pharmacokinetics and efficacy of once daily amikacin for treatment of Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Pharmacokinetics of once-daily versus thrice daily tobramycin in cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Continuous infusion of beta-lactam antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Continuous infusion of ceftazidime in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Continuous infusion of ceftazidime in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Pharmacokinetics of antibiotics in cystic fibrosis patients with particular reference to the bronchopulmonary tree (review).

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Burkholderia cepacia. Management issues and new insights.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Non-tuberculous mycobacteria in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Pulmonary function in hospitalized infants and toddlers with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Nutritional impact of antipseudomonas intravenous antibiotic courses in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Efficacy of aerosolized tobramycin in patients with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Effectiveness of home versus hospital care in the routine treatment of cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

High-level beta-lactamase activity in sputum samples from cystic fibrosis patients during antipseudomonal treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Role of anti-pseudomonal antibiotics in the emergence of Stenotrophomonas maltophilia in cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Case-control and vector studies of nosocomial acquisition of Pseudomonas cepacia in adult patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Renal function in cystic fibrosis: proteinuria and enzymuria before and after tobramycin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Urinary N-acetyl-beta-D-glucosaminidase activity in patients with cystic fibrosis on long-term gentamicin inhalation

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Loss of spiral ganglion cells as primary manifestation of aminoglycoside ototoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Rheumatologic aspects of pediatric cystic fibrosis patients treated with fluoroquinolones

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Cystic Fibrosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Retrospective clinical study of hypersensitivity reactions to aztreonam and six other beta-lactam antibiotics in cystic fibrosis patients receiving multiple treatment courses

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Intravenous desensitization to ceftazidime in cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

Fever associated with intravenous antibiotics in adults with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2800%2980134-7

7 January 2021

10.1016/S0929-693X(00)80134-7

Identifiers

DOI

1 reference

24 May 2018

PubMed ID

10911533

1 reference

24 May 2018